A transatlantic biotechnology company specialising in novel protein engineering technologies
Avenue Biosciences has raised €7.2M across 2 funding rounds from 7 investors, most recently a Seed round in Jan 2026. Based in Helsinki, Finland; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-01-12 | Seed | €4.9M | Balnord,Dimerent,Inventure,Tesi,University of Helsinki,Voima Ventures | View deal → |
| 2024-10-22 | Seed | €2.3M | Angel Investors,Inventure,Voima Ventures | View deal → |
